Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 4:57 PM
Ignite Modification Date: 2025-12-25 @ 2:39 PM
NCT ID: NCT02756650
Description: An AE is any sign or symptom that occurs during the study treatment plus the # days post treatment
Frequency Threshold: 5
Time Frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment
Study: NCT02756650
Study Brief: 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
ACZ885N Canakinumab 0 None 0 8 8 8 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Middle ear inflammation SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders MedDRA (22.1) View
Swelling of eyelid SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (22.1) View
Abdominal pain upper SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (22.1) View
Aphthous ulcer SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (22.1) View
Gastrooesophageal reflux disease SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (22.1) View
Folliculitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (22.1) View
Influenza SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (22.1) View
Pilonidal cyst SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (22.1) View
Rash pustular SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (22.1) View
Rhinitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (22.1) View
Tonsillitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (22.1) View
Alanine aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (22.1) View
Aspartate aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (22.1) View
Hepatic enzyme increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (22.1) View
Arthralgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (22.1) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (22.1) View
Nystagmus SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (22.1) View
Tension headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (22.1) View
Haematuria SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA (22.1) View
Nephrolithiasis SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA (22.1) View
Genital ulceration SYSTEMATIC_ASSESSMENT Reproductive system and breast disorders MedDRA (22.1) View
Testicular swelling SYSTEMATIC_ASSESSMENT Reproductive system and breast disorders MedDRA (22.1) View
Haemoptysis SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (22.1) View
Oropharyngeal pain SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (22.1) View
Pulmonary artery aneurysm SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (22.1) View
Acne SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (22.1) View
Erythema nodosum SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (22.1) View
Thrombophlebitis superficial SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (22.1) View